Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Al Mayadeen's correspondent: One was killed, another injured in a raid by an Israeli drone on the city of Khiam in South Lebanon
London views possibility of setting fire to tanker in port of friendly country to Russia to damage port infrastructure, initiate an international probe: Moscow
One of London's scenarios involves setting up accident with 'undesirable' tanker in one of the bottlenecks of maritime communications: Russian foreign intelligence agency
London plans to organize major sabotage with tankers to declare transportation of Russian oil to international shipping: Russian foreign intelligence agency
UK intelligence agencies plan to use NATO allies to launch massive raid on 'Shadow Fleet': Russian foreign intelligence agency
Palestinian Ministry of Health: Two were martyred in Israeli shelling that targeted a besieged house in the town of Qabatiya in Jenin
At least 68 dead in migrant shipwreck off Yemen: IOM
Trump: We want to feed the people in Gaza, we do not want them to starve.
US President Donald Trump: We will impose sanctions on Russia if it does not end the war on Ukraine.
Israeli media: Polls show that 52% oppose Prime Minister Benjamin Netanyahu while only 29% support him.

‘Breakthrough’ drugs shrink tumors in half ovarian cancer patients

  • By Al Mayadeen English
  • Source: Agencies
  • 4 Jun 2023 13:21
2 Min Read

The groundbreaking therapy has been found to drastically prevent tumor development, allowing the illness to be kept at bay for years.

  • x
  • An intern at the Hampton University Cancer Research Centre in Virginia, the US, examines cancer cells. (AP)
    An intern at the Hampton University Cancer Research Centre in the US examining cancer cells (AP)

Thousands of women with ovarian cancer may benefit from a groundbreaking medicine combination that has been demonstrated to considerably decrease tumors in nearly half of patients with the condition.

The new medication inhibits tumor development, which can help put the cancer at bay for years. The "fantastic" and "very exciting" findings of clinical trials of the medicine combination, presented this weekend at the world's largest cancer conference, revealed it was "far more effective" than any other existing alternative for patients, as per experts.

The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London conducted a phase 2 study on 29 patients to evaluate the medicine Avutometinib alone and in combination with Defactinib.

According to trial data, over half of the patients on the new medicine combination had their tumors shrink considerably. It was nearly twice as successful as the next best therapy, trametinib, which had a 26% response rate.

Patients with a specific mutation had even better results, with 60% of KRAS-driven ovarian tumors shrinking following therapy.

However, nearly a third of patients (29%) who did not have the mutation had an optimistic response, which is an improvement over usual therapy.

All of the patients had low-grade serous ovarian cancer, which is more common in young women.

Dr. Susana Banerjee, the global lead investigator of the study presented at the American Society of Clinical Oncology’s annual meeting in Chicago, affirmed that the new drug could represent a “significant breakthrough”.

“These initial results could be fantastic news for women with low-grade serous ovarian cancer, indicating a far more effective option than current treatments,” she said.

It is worth noting that Avutometinib is a dual RAF and MEK inhibitor, which is a sort of targeted medicine that inhibits specific proteins that aid in cancer development and survival. According to research, the medicine might become ineffective over time as tumors acquire treatment resistance.

However, when paired with Defactinib, which combats a protein that promotes treatment resistance, Avutometinib performs better. The medication combination outperforms Avutometinib alone by a factor of four.

Read next: New cancer treatment offers hope to patients out of options

  • defactinib
  • Cancer
  • Avutometinib
  • ovarian cancer

Most Read

A rescued crew member from the ETERNITY C vessel in a video released by the Yemeni Armed Forces on July 28, 2025 (Yemeni Military Media)

Yemen Navy reveals fate of targeted Eternity C ship crew

  • Politics
  • 28 Jul 2025
An Israeli tank explodes following an ambush by al-Qassam Brigades in Gaza, Occupied Palestine, undated (Al-Qassam Military Media)

Al-Qassam strikes Israeli vehicles in Gaza, inflicts casualties

  • Politics
  • 30 Jul 2025
UAE lodges complaint against Israeli ambassador over 'misbehavior'

UAE lodges complaint against Israeli ambassador over 'misbehavior'

  • Politics
  • 1 Aug 2025
Protesters chant anti-Israeli slogans as they carry a banner that reads:" Freedom for Palestine, Alliance stop the war," during a demonstration in support of Palestinians in Gaza, outside the Israeli embassy, in Athens, Monday, June 9, 2025 (AP)

Athens mayor slams Israeli ambassador over Gaza war, graffiti claim

  • Politics
  • 3 Aug 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
A member of the al-Qassam Brigades, the armed wing of Hamas, takes part in a parade as he celebrates a ceasefire agreement between Hamas and the Israeli regime in Deir al-Balah, Gaza Strip, Sunday, January 19, 2025 (AP)
Politics

Al-Qassam: We’ll allow aid to Israeli captives if Gaza siege ends

Freed Lebanese freedom fighter Georges Abdallah during an interview on Al Mayadeen, which aired on Sunday, August 3, 2025 (Al Mayadeen screengrab)
Politics

Exclusive: Resistance key to building state, Georges Abdallah says

United Nations Secretary General Antonio Guterres gives a statement about the situation in Gaza at UN headquarters, Friday, June 27, 2025 (AP)
Politics

UN warns Gaza faces water crisis, looming famine under Israeli siege

Israeli soldiers drive their armored personnel carrier along the Gaza Strip, in southern occupied Palestine, Wednesday, July 30, 2025 (AP)
Politics

Ex-Israeli general says Gaza starvation campaign isolated 'Israel'

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS